



LKT Laboratories, Inc.

AZD-1480

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A9812

CAS No. 935666-88-9

Chemical Name

Synonym AZD-1480

Formula $C_{14}H_{14}ClFN_8$

Formula Wt. 348.77

Melting Point


Purity $\geq 98\%$

Solubility DMSO 69 mg/mL warmed (197.83 mM)
Water Insoluble
Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description AZD-1480 is an inhibitor of JAK1/2 that exhibits antiviral, immunosuppressive, anti-metastatic, and anticancer chemotherapeutic activities. In vitro, AZD-1480 inhibits replication of hepatitis A virus. In animal models of experimental autoimmune encephalitis (EAE), AZD-1480 decreases disease severity by suppressing expression of inflammatory cytokines and minimizing antigen presentation and T cell expansion. In animal models of various cancers, this compound inhibits tumor growth. AZD-1480 is currently in clinical trials as a potential cancer treatment. In cellular and animal models of prostate cancer, this compound inhibits metastasis.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A9812	1 mg	\$75.00
A9812	5 mg	\$100.00
A9812	10 mg	\$175.00

References Jiang X, Kanda T, Nakamoto S, et al. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. *Biochem Biophys Res Commun*. 2015 Feb 19. [Epub ahead of print]. PMID: 25704089.

Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. *Mol Cancer Ther*. 2015 Feb 2. [Epub ahead of print]. PMID: 25646015.

Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. *Mol Cancer Ther*. 2015 Feb;14(2):364-74. PMID: 25504635.

Houghton PJ, Kurmasheva RT, Lyalin D, et al. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. *Pediatr Blood Cancer*. 2014 Nov;61(11):1972-9. PMID: 25131802.

Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. *Mol Cancer Ther*. 2014 May;13(5):1246-58. PMID: 24577942.

Liu Y, Holdbrooks AT, De Sarno P, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. *J Immunol*. 2014 Jan 1;192(1):59-72. PMID: 24323580.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.